Ménière’s disease: hearing and vertigo, diagnostic categories, hydrops, treatment goals, and uncertain evidence

Endolymph is normal inner-ear fluid

NIDCD explains that the membranous labyrinth contains endolymph around hearing and balance structures. Abnormal buildup, called endolymphatic hydrops, is associated with disrupted signaling. The underlying causes remain unclear, with several proposed mechanisms. “Fluid imbalance” is not proof of one dietary cause, an infection in every case or a toxin requiring cleansing.[1]

The 2015 consensus distinguishes two clinical categories

The combination and time course matter

NIDCD describes at least two spontaneous episodes for definite disease, documented hearing loss and exclusion of another explanation. There is no single definitive symptom or test. A hearing test, episode history and clinical assessment do more than matching “ringing plus dizziness” to a search result.[1]

The Bárány-led consensus supplies diagnostic categories rather than a universal treatment ranking. Its probable category is not simply the definite category with the same time window but a missing test result. Definitions matter when comparing research: enrolling different populations can change what a study answers.[3]

A familiar label should not conceal a new emergency

New facial droop, arm weakness, speech difficulty or visual disturbance with vertigo needs emergency help. Do not drive yourself. The NHS cautions that other conditions can mimic Ménière’s symptoms.[2]

Treatment can address several different problems

NIDCD distinguishes attack medicines, rehabilitation for chronic imbalance, hearing support and selected procedures. Relieving vertigo, preserving hearing and improving daily function are separate aims; an improvement in one does not establish a cure.[1]

Clinical guidance and a placebo comparison answer different questions

The 2020 AAO-HNSF guideline aims to improve diagnostic accuracy and appropriate symptom care while reducing unnecessary medicines, procedures and tests. It is not a comprehensive management text for every mimic or presentation. A clinician’s reason to offer an option and strong randomized proof of its benefit are related but separate judgments.[4]

Gentamicin aims to reduce balance function in the affected ear

The 2023 gentamicin review explains that this intratympanic treatment aims to partially or completely destroy affected-ear balance function. That mechanism differs from treating an assumed bacterial infection. It can also harm hearing; fewer vertigo attacks and preservation of hearing are separate outcomes.[9]

Five small trials included 137 participants. The reviewers rated the evidence very low certainty, with inconsistent methods and time points. Some results suggested vertigo improvement, but serious harms were not adequately reported. Missing safety data do not show that a destructive treatment is harmless or predict an individual benefit–harm balance.[9]

Care includes practical access and repeated outcome assessment

The AAO-HNSF guideline identifies variable access to audiograms, imaging, therapies and specialists, alongside barriers to education. Research needs include consistent disease stages and response definitions. Recording hearing, vertigo, daily function, treatment burden and harms separately helps make a claim more interpretable than a single “success rate.”[4]

Published questions

Commonly offered maintenance medicines have evidence limits

The 2023 systemic-treatment review included 10 studies with 848 participants across betahistine, diuretics, antivirals and corticosteroids. Seven betahistine trials included 548 participants. Outcomes, measurement methods and follow-up differed, preventing useful pooling for the main comparisons. The reviewers reported low or very low certainty; those are their assessments, not a new Atlas grade.[5]

That review concerned preventive systemic treatment with sustained follow-up, rather than proving that all short-term attack relief is ineffective. Uncertain estimates also do not demonstrate that every option works equally well or that no patient can benefit. They limit confident claims about comparative effects and harms.[5]

BEMED illustrates why uncontrolled improvement can mislead

The 2016 BEMED trial randomized 221 adults with definite disease to placebo or two betahistine dose groups for nine months. Attack incidence did not differ significantly between groups. Attacks declined overall, including with placebo. That pattern makes “I started it and attacks decreased” insufficient evidence of a treatment-specific effect.[11]

The investigators could not separate spontaneous fluctuation from placebo-related effects without a no-intervention group. The study reported German public research support and disclosed competing interests separately. It is one selected trial, also part of the broader evidence context, not an independent replication of every conclusion in later reviews.[11]

The older dietary review did not establish one effective restriction

The 2023 Cochrane diet review found two relevant trials of different interventions and low or very low certainty. Its September 2022 search found no eligible placebo-controlled trials of commonly recommended salt or caffeine restriction. This is a dated search result, not proof that later trials cannot exist or that diet has no effect.[6]

A 2024 trial tested a combined approach in a selected population

A later trial randomized 50 people with stage-3 unilateral disease. Both groups received routine medication; one also used a low-sodium diet with specified water intake. The authors reported better hearing measures and tinnitus/dizziness questionnaire changes with the combined intervention. It postdates the review’s search and should remain visible alongside that older assessment.[7]

This small study did not isolate salt from water or establish the best approach for every disease stage. Its abstract does not fully resolve blinding, durability or clinically important absolute benefit. It reported no funding or potential conflicts. The findings justify closer appraisal, not copying an intake target into a universal self-treatment rule.[7]

Operations differ in what function they aim to preserve

The 2023 surgical review distinguishes procedures intended to preserve hearing from destructive approaches that eliminate balance function and may sacrifice hearing. Its eligible randomized evidence covered only two of five planned comparisons. Small studies, incomplete outcomes and low or very low certainty prevented clear efficacy conclusions.[10]

This does not make every operation equivalent or establish a guaranteed cure. The actual procedure, remaining hearing, symptom burden, prior care and potential irreversible harms need separate explanation. This selected review cannot supply a personal surgical recommendation or settle every modern procedural comparison.[10]

Injection studies do not remove uncertainty about sustained benefit

The 2023 steroid-injection review included 10 studies with 952 participants, all using dexamethasone. It found little difference in reported vertigo improvement at later follow-up; a possible small short-term frequency benefit was uncertain. Measures and time points mattered, and safety estimates remained uncertain.[8]

The review also identified two large unpublished trials understood not to show benefit. Missing results can affect an apparently favorable published literature. Its low or very low certainty and September 2022 search date belong with the findings. This comparison does not establish one best injection schedule or all corticosteroids as interchangeable.[8]

References

1. Ménière’s Disease

   Agency condition or prevention explanation

   NIDCD · Content/publication date: 2024
   Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
   Cited sections: June 2024 publication, August update: symptom course, endolymph/hydrops, diagnostic combination and cause uncertainty

   Current explanation inspected; population statistics and specific intake targets not adopted as personal guidance.

2. Ménière’s disease

   Agency condition or prevention explanation

   NHS · Content/publication date: 2026
   Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
   Cited sections: September 2026: overlapping symptoms and emergency neurological changes

   Shared source; UK guidance.

3. Diagnostic criteria for Menière’s disease

   Professional diagnostic consensus

   Lopez-Escamez JA and Bárány-led international consensus group; Journal of Vestibular Research · Content/publication date: 2015
   Accessed: 2026-10-08 UTC · Original indexed publisher abstract and publication metadata inspected
   Cited sections: 2015 original abstract: definite/probable categories, hearing pattern and differing duration windows

   Diagnostic consensus, not an individual diagnosis or treatment ranking.

4. Clinical Practice Guideline: Ménière’s Disease

   Professional guidance

   Basura GJ and AAO-HNSF; Otolaryngology–Head and Neck Surgery · Content/publication date: 2020
   Accessed: 2026-10-08 UTC · Selected original indexed guideline purpose and implementation passages inspected; full action statements not independently appraised
   Cited sections: 2020 original selected purpose, scope, implementation barriers and research-needs passages

   Dated practice framework; no claim of complete contemporary guideline reconciliation.

5. Systemic pharmacological interventions for Ménière’s disease

   Systematic review

   Webster KE and Cochrane ENT · Content/publication date: 2023
   Accessed: 2026-10-08 UTC · Original indexed review summary and selected methods/results inspected; no independent full-text appraisal
   Cited sections: 2023 original abstract: 10 studies, heterogeneous comparisons and reported certainty

   Search through September 14, 2022; published review certainty, not independent Atlas grading.

6. Lifestyle and dietary interventions for Ménière’s disease

   Systematic review

   Webster KE and Cochrane ENT · Content/publication date: 2023
   Accessed: 2026-10-08 UTC · Original review summary and selected methods/results inspected; no independent full-text appraisal
   Cited sections: February 2023: two trials, comparator scope, missing eligible restriction trials and uncertainty

   Search through September 14, 2022; later 2024 trial separately explained.

7. Low-sodium diet with adequate water intake improved the clinical efficacy in Ménière’s disease

   Original randomized trial

   Yang X and colleagues; Acta Oto-Laryngologica · Content/publication date: 2024
   Accessed: 2026-10-08 UTC · Original indexed abstract and selected original result passages inspected; no independent full-text appraisal
   Cited sections: February 2024 online: 50 stage-3 unilateral patients, combined intervention, comparator and reported measures

   Abstract and publisher disclosure inspected; no funding/conflicts declared, full methods and long-term results not independently appraised.

8. Intratympanic corticosteroids for Ménière’s disease

   Systematic review

   Webster KE and Cochrane ENT · Content/publication date: 2023
   Accessed: 2026-10-08 UTC · Original review summary and selected methods/results inspected; no independent full-text appraisal
   Cited sections: February 2023: 10 studies, outcome/time differences, safety uncertainty and missing large trials

   Search through September 14, 2022; dexamethasone evidence and published certainty retained.

9. Intratympanic gentamicin for Ménière’s disease

   Systematic review

   Webster KE and Cochrane ENT · Content/publication date: 2023
   Accessed: 2026-10-08 UTC · Original indexed review summary and selected methods/results inspected; no independent full-text appraisal
   Cited sections: 2023 original abstract: destructive mechanism, five trials, very low certainty and missing harms

   Search through September 14, 2022; selected original indexed review sections, not independent full-text appraisal.

10. Surgical interventions for Ménière’s disease

    Systematic review

    Cochrane ENT review team · Content/publication date: 2023
    Accessed: 2026-10-08 UTC · Original indexed review summary and selected methods/results inspected; no independent full-text appraisal
    Cited sections: 2023 original abstract and intervention sections: functional tradeoffs, limited comparisons and reported certainty

    Search through September 14, 2022; incomplete harms and outcomes do not establish equivalence.

11. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: BEMED trial

    Original randomized trial

    Adrion C and BEMED Study Group; BMJ · Content/publication date: 2016
    Accessed: 2026-10-08 UTC · Original indexed abstract and selected original result passages inspected; no independent full-text appraisal
    Cited sections: January 2016: 221 participants, three groups, nine months, attack incidence and fluctuation limits

    Public German support reported; full declared interests/methods not independently appraised. Trial overlaps subsequent review evidence.

Scope & review

Population

Hearing/balance literacy; probable/definite diagnostic categories, variable course, selected adult treatment trials and unilateral stage-3 diet population distinguished

Exposure or intervention

Clinical assessment, symptom/communication care, maintenance approaches, combined dietary intervention, injections and surgery

Comparison

Source-specific symptom, care, screening or comparator settings

Outcomes

Vertigo frequency, hearing, tinnitus, functional burden, quality of life, durable control and treatment harms

Timeframe

Repeated attacks, nine-month selected trial and dated 2015–2026 sources; 2023 review searches ended September 2022

Jurisdiction

Selected US/UK agency and professional guidance; jurisdiction and eligibility differences are labeled

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

What this article still leaves open

• Independent ENT review, full current practice-guideline and post-2023 trial reconciliation, intervention-specific long-term hearing/vertigo outcomes and pediatric/pregnancy evidence remain incomplete.
• No Ménière’s diagnosis, sodium/fluid target, medicine dose, injection schedule, surgical choice, exercise plan, driving clearance or personal chance of remission is selected.

Related reading

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.